Fresh Equities
Raises
Research
About
Looking for more information?

Contact our responsive and friendly client services team any time.

RECCE PHARMACEUTICALS LTD

INVESTOR PRESENTATION - RECCE PHARMACEUTICALS LTD

ASX:RCE

RECCE PHARMACEUTICALS LTD

Health Care

Recce Pharmaceuticals Ltd (ASX:RCE) is an Australian based globally-focussed, biotechnology company engaged in the development and commercialisation of a new class of antibiotics. RCE's portfolio of antibiotic therapies seek to address health threats posed by drug resistant bacteria. Their lead candidate RECCE®327 is designed as abroad-spectrum antibiotic, formulated using synthetic polymer technology to treat bacterial sepsis (blood poisoning) and other bacterial infections, including superbugs.

Read more

Market Cap

$196.20m

Price at Close

$1.13

4w avg. Volume

284.89k

4w avg. Turnover

$311.02k

Announcements
announcementt+2 movementdate
  • Recce Awarded AusIndustry Advanced Overseas (R&D) Finding

    Progress Report · Market sensitive

  • -

    25 Nov 2020

-

25 Nov 2020
  • Anti-Viral Patent Granted in Japan for RECCE Anti-Infectives

    Progress Report · Market sensitive

  • -2.59%

    22 Nov 2020

-2.59%

22 Nov 2020
  • Reinstatement to Official Quotation

    Stock Exchange Announcement · Market sensitive

  • +0.46%

    10 Nov 2020

+0.46%

10 Nov 2020
  • Encouraging Results Against SARS-CoV-2 Virus

    Progress Report · Market sensitive

  • +0.46%

    10 Nov 2020

+0.46%

10 Nov 2020
  • Extension of Voluntary Suspension

    Company Administration

  • +13.68%

    09 Nov 2020

+13.68%

09 Nov 2020
  • Extension of Voluntary Suspension

    Company Administration

  • +13.68%

    08 Nov 2020

+13.68%

08 Nov 2020
  • Suspension from Official Quotation

    Stock Exchange Announcement · Market sensitive

  • 0.00%

    04 Nov 2020

0.00%

04 Nov 2020
  • Trading Halt

    Stock Exchange Announcement · Market sensitive

  • 0.00%

    02 Nov 2020

0.00%

02 Nov 2020
  • Letter to Shareholders - Annual General Meeting

    Notice Of Meeting

  • -7.32%

    30 Oct 2020

-7.32%

30 Oct 2020
  • Notice of Annual General Meeting/Proxy Form

    Notice Of Meeting

  • -7.32%

    30 Oct 2020

-7.32%

30 Oct 2020
Market Data

Current Price

$1.13

52WK HIGH

$1.875

52WK LOW

$0.21

1YR RETURN

+334.62%

1YR RETURN VS. SECTOR

-1493.46%

90 DAY RETURN

-17.22%

ASX RANK

588

/2,024

SECTOR RANK

7

/32

SHARES OUTSTANDING

173.63m
ASX:RCE

RECCE PHARMACEUTICALS LTD

Health Care

Recce Pharmaceuticals Ltd (ASX:RCE) is an Australian based globally-focussed, biotechnology company engaged in the development and commercialisation of a new class of antibiotics. RCE's portfolio of antibiotic therapies seek to address health threats posed by drug resistant bacteria. Their lead candidate RECCE®327 is designed as abroad-spectrum antibiotic, formulated using synthetic polymer technology to treat bacterial sepsis (blood poisoning) and other bacterial infections, including superbugs.

Read more

Market Cap

$196.20m

Price at Close

$1.13

4w avg. Volume

284.89k

4w avg. Turnover

$311.02k

ASX:RCE is not raising right now

Want to invest?

Fresh Equities

Copyright © 2020 Fresh Equities. All rights reserved. ACN 619 657 028. CAR: 001267539 of AFSL: 471379.

Contact Us

(03) 9028 2888

clients@freshequities.com

Address

Level 7, 388 Bourke St
Melbourne VIC 3000
Australia

Copyright © 2020 Fresh Equities. All rights reserved. ACN 619 657 028. CAR: 001267539 of AFSL: 471379.